Novartis opens cell and gene therapy facility ahead of time

By Ben Hargreaves

- Last updated on GMT

(Image: Getty/BrianAJackson)
(Image: Getty/BrianAJackson)

Related tags Novartis Cell therapy Kymriah Switzerland

The Swiss manufacturing facility will be responsible for the manufacture of cell and gene therapies, including Kymriah.

When the facility was originally announced, in August 2018​, it was projected to be completed in early 2020, but the company has managed to ready the CHF 90m (€79m) facility earlier than this timeline.

According to the company​, the first clinical production of a cell and gene therapy batch was completed in September 2019, at the newly opened Stein, Switzerland facility.

After the European approval​ for Kymriah (tisagenlecleucel), the company has focused on building out capacity to meet demand in the region.

This includes acquiring its former manufacturing partner for Kymriah, when it purchased CellforCure​. At the time of the announcement, Novartis revealed that production of Kymriah would begin by mid-2019 after the deal had been completed.

The Stein facility will also focus on the production of chimeric antigen receptor (CAR)-T therapies, with commercial production expected to be completed in the first quarter of 2020, subject to regulatory approval.

At present, the facility has created 185 positions in cell and gene therapy, with a further 265 expected to be added over the next few years.

Producing Kymriah has not been without its difficulties for the Swiss company, with it previously telling investors that it had struggled with meeting product specifications​.

As a result, the company pledged to invest into its cell therapy manufacturing network​ and to speed up the process of digitization, whilst also moving investment away from traditional production technologies.

In third quarter financials, Kymriah was able to repay some of this investment with strong growth, after making $79m (€71m) in the third quarter – representing growth of 295% over the previous year’s results, though these were released shortly after the product gained European approval.

In addition to the investment in cell and gene manufacture and announcing that it was looking away from traditional processing, Novartis also stated that the new facility would hold capabilities to produce solid dosage forms, including tablets and capsules.

Related news

Show more

Related products

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Related suppliers

Follow us


View more